

PATENT
ATTORNEY DOCKET NO.: 056291-5179

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re PATENT APPLICATION of:

NEWCOMBE et al.

Application No.: 10/507,169

Filed: September 9, 2004

FOR: 4-IMIDAZOLYL SUBSTITUTED
PYRIMIDINE DERIVATIVES WITH CDK
INHIBITORY ACTIVITY

Group Art Unit:

Examiner:

Commissioner for Patents
U.S. Patent and Trademark Office
Customer Service Window, Mail Stop _____
Randolph Building
401 Dulany Street
Alexandria, VA 22314

Date: February 15, 2005

Sir:

INFORMATION DISCLOSURE STATEMENT

Citation of Related U.S. Patent Applications

The Examiner's attention is directed to the following related co-pending U.S. patent applications:

| Examiner's Initials | Inventor | U.S. Serial No. U.S. Filing Date | U.S. Patent No. Issued: | PCT Publication No. PCT Publication Date |
|---------------------|-----------------|-------------------------------------|----------------------------|---|
| | Breault et al. | 09/763,705 02/26/2001 | | WO 00/12485 Mar 9, 2000 |
| | Breault et al. | 10/771,118 02/04/2004 | | WO 00/12485 Mar 9, 2000 |
| | Breault et al. | 09/763,681 02/26/2001 | 6,632,820 10/14/2003 | WO 00/12486 March 9, 2000 |
| | Bradbury et al. | 09/868,602 06/20/2001 | 6,593,326 07/15/2003 | WO 00/39101 July 6, 2000 |
| | Breault et al. | 09/914,788 09/05/2001 | 6,716,831 04/06/2004 | WO 00/53595 Sept. 14, 2000 |

| Examiner's Initials | Inventor | U.S. Serial No. U.S. Filing Date | U.S. Patent No. Issued: | PCT Publication No. PCT Publication Date |
|---------------------|-----------------|-------------------------------------|----------------------------|---|
| | Breault | 09/958,077 10/04/2001 | 6,670,368 12/30/2003 | WO 00/59892 Oct. 12, 2000 |
| | Pease et al. | 10/203,154 08/06/2002 | 6,649,608 11/18/2003 | WO 01/64655 Sept. 7, 2001 |
| | Pease et al. | 10/220,139 08/28/2002 | | WO 01/64654 Sept. 7, 2001 |
| | Pease et al. | 10/203,025 08/05/2005 | 6,838,464 01/04/2005 | WO 01/64656 Sept. 7, 2001 |
| | Pease et al. | 10/995,931 11/24/2004 | | WO 01/64656 Sept. 7, 2001 |
| | Pease et al. | 10/203,549 08/08/02 | 6,710,052 03/23/2004 | WO 01/64653 Sept. 7, 2001 |
| | Pease et al. | 10/753,959 01/09/2004 | | WO 01/64653 Sept. 7, 2001 |
| | Thomas et al. | 10/069,019 02/21/2002 | 6,855,719 02/15/05 | WO 01/14375 A1 March 1, 2001 |
| | Thomas | 10/239,790 09/25/2002 | | WO 01/72717 Oct. 4, 2001 |
| | Thomas et al. | 10/332,275 01/07/2003 | Allowed 10/08/2004 | WO 01/04429 Jan. 17, 2002 |
| | Breault et al. | 10/363,655 03/04/2003 | | WO 02/20512 Mar. 14, 2002 |
| | Thomas | 10/467,886 08/13/2003 | 6,844,341 01/18/05 | WO 02/066481 A1 Aug. 29, 2002 |
| | Newcombe | 10/479,041 11/26/2003 | | WO 02/096887 A1 Dec. 5, 2002 |
| | Newcombe et al. | 10/507,162 09/09/2004 | | WO 03/076435 A1 Sept. 18, 2003 |
| | Newcombe et al. | 10/507,081 09/09/2004 | | WO 03/076436 A1 Sept. 18, 2003 |
| | Newcombe et al. | 10/507,163 09/09/2004 | | WO 03/076433 A1 Sept. 18, 2003 |

A copy of the specification and claims for each application, in the form of the published PCT application from which such application was filed, has previously been provided or is being filed herewith. Copies of the U.S. patent documents are not enclosed.

PLEASE DO NOT PRINT the above information on the patent resulting from the subject application.

Consideration of each listed application is earnestly solicited since unpublished patent applications are contemplated as IDS material; see the exception in Rule 98(a)(2)(iii) and note the penultimate sentence of MPEP 609.

Further, in keeping with MPEP 609, Subsec. C(2), 2nd para., line 10 to end of the paragraph (especially note lines 18-25) PLEASE RETURN A COPY OF THIS LETTER with the Examiner's initials adjacent each above listing so that applicant will know that each listed application has been considered as required by PTO policy.

Citation of Documents

Attached is a Form PTO-1449 listing the enclosed foreign patent documents. Copies of the U.S. patent documents are not enclosed.

The present Information Disclosure Statement is being filed before the mailing date of the first Office Action on the merits, and therefore no certification under 37 CFR §1.97(e) or fee under 37 CFR §1.17(p) is required.

Should a first Action on the merits have been issued on the same day as or before this IDS is filed, please accept this IDS under Rule 97(c) and charge the requisite fee to our Deposit Account under Order No. 056291-5179 and proceed to consider this IDS.


This Information Disclosure Statement is intended to be in full compliance with the rules, but should the Examiner find any part of its required content to have been omitted, prompt notice to that effect is earnestly solicited, along with additional time under Rule 97(f), to enable Applicant to fully comply.

Consideration of the foregoing and enclosures plus the return of a copy of the herewith filed Form PTO-1449 with the Examiner's initials in the left column per MPEP 609 along with an early action on the merits of this application are earnestly solicited.

Except for issue fees payable under 37 C.F.R. §1.18, the Director is hereby authorized by this paper to charge any additional fees during the entire pendency of this application including fees due under 37 C.F.R. §§1.16 and 1.17 which may be required, including any required

extension of time fees, or credit any overpayment to Deposit Account No. 50-0310. This paragraph is intended to be a **CONSTRUCTIVE PETITION FOR EXTENSION OF TIME** in accordance with 37 C.F.R. §1.136(a)(3).

Respectfully Submitted,
Morgan Lewis & Bockius LLP



Date: February 15, 2005
Morgan Lewis & Bockius LLP
Customer No. **09629**
1111 Pennsylvania Avenue, N.W.
Washington, D.C. 20004
Tel. No.: 202-739-3000
DJB:mk

By:

Donald J. Bird
Registration No. 25,323
Tel. No.: (202) 739-5320
Fax No.: (202) 739-3001

| | | | | | | | | |
|---|--|--|--|--|--------------------------------|--|----------------------------|--|
| FORM PTO-1449 (modified) To: U.S. Department of Commerce Patent and Trademark Office INFORMATION DISCLOSURE STATEMENT BY APPLICANT Date: February 15, 2005 | | | | | Attorney Docket No. | | Client Ref. | |
| | | | | | 056291-5179 | | | |
| | | | | | Applicant: NEWCOMBE et al. | | | |
| | | | | | Appln. No.: 10/507,169 | | | |
| | | | | | Filing Date: September 9, 2004 | | | |
| | | | | | Examiner: Unassigned | | Group Art Unit: Unassigned | |

| FOREIGN PATENT DOCUMENTS | | | | | | English Abstract | | Translation Readily Available | |
|--------------------------|----|-----------------|--------------|---------|-------------------------|------------------|----|-------------------------------|----|
| | | Document Number | Date MM/YYYY | Country | Inventor/Applicant Name | Enclosed | No | Enclosed | No |
| | AR | 01/29009 A1 | 04/2001 | WO | Davis et al. | | | | |
| | BR | 01/30778 A1 | 05/2001 | WO | Révész et al. | | | | |
| | CR | 01/47897 A1 | 07/2001 | WO | Moriarty et al. | | | | |
| | DR | 01/47921 A1 | 07/2001 | WO | Erickson et al. | | | | |
| | ER | 01/60816 A1 | 08/2001 | WO | Armstead et al. | | | | |
| ** | FR | 01/64653 A1 | 09/2001 | WO | Pease et al. | | | | |
| ** | GR | 01/64655 A1 | 09/2001 | WO | Pease et al. | | | | |
| ** | HR | 01/64656 A1 | 09/2001 | WO | Pease et al. | | | | |
| ** | IR | 01/72717 A1 | 10/2001 | WO | Thomas et al. | | | | |
| ** | JR | 02/066481 A1 | 08/2002 | WO | Thomas | | | | |
| ** | KR | 02/096887 A1 | 12/2002 | WO | Newcombe et al. | | | | |
| ** | LR | 03/076433 A1 | 09/2003 | WO | Newcombe et al. | | | | |
| ** | MR | 03/076435 A1 | 09/2003 | WO | Newcombe et al. | | | | |
| ** | NR | 03/076436 A1 | 09/2003 | WO | Newcombe et al. | | | | |
| | OR | 03/007955 A2 | 01/2003 | WO | Hickson et al. | | | | |

| OTHER (Including in this order Author, Title, Periodical Name, Date, Pertinent Pages, etc.) | | | | | | | | | |
|---|----|---|--|--|--|--|---|--|---|
| | PR | Boschelli et al., "Synthesis and Tyrosine Kinase Inhibitory Activity of a Series of 2-Amino-8- <i>H</i> -pyrido[2,3- <i>d</i>]pyrimidines: Identification of Potent, Selective Platelet-Derived Growth Factor Receptor Tyrosine Kinase Inhibitors, J. Med. Chem., Vol. 41, 1998, pp. 4365-4377 | | | | | | | |
| | QR | Deady et al., "Reactions of some Quinazoline Compounds with Ethoxymethylenemalononic Acid Derivatives", J. Heterocyclic Chem., Vol. 26, 1989, pp. 161-168 | | | | | | | |
| | RR | El-Kerdawy et al.; "2,4-Bis (Substituted)-5-Nitropyrimidines of Expected Diuretic Action"; Egypt J. Chem. Vol. 29, No. 2, 1986, pp. 247-251 | | | | | | | |
| | SR | Fiziol Akt Veshchestva, 1975, Vol. 7, pp. 68-72 | | | | | X | | X |
| | TR | Ghosh et al.; "2,4-Bis(aryl amino)-5-methylpyrimidines as Antimicrobial Agents"; J. Med. Chem., 1967, Vol. 10, No. 5, pp. 974-975; | | | | | | | |
| | UR | Ghosh, "2,4-Bis(Arylamino)-6-Methyl Pyrimidines as Antimicrobial Agents", J. Indian Chem. Soc., Vol. 58, No. 5, 1981, pp. 512-513 | | | | | | | |
| | VR | Schmidt et al.; "A Convenient Synthesis of 2-substituted 4-Amino-5-pyrimidinecarbonitriles"; J. Heterocycle Chem., 1997, Vol. 24, No. 5, pp. 1305-1307 | | | | | | | |
| | WR | Zimmermann et al., "Phenylamino-Pyrimidine (PAP) Derivatives: A New Class of Potent and Selective Inhibitors of Protein Kinase C (PKC), Arch. Pharm. Pharm. Med. Chem., Vol. 329, 1996, pp. 371-376 | | | | | | | |

| | |
|----------|------------------|
| Examiner | Date Considered: |
|----------|------------------|

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.